SCHEMBL1780255

SCHEMBL1780255

CC1(c2ccc(Cl)c(C(F)(F)F)c2)CC(CO[Si](c2ccccc2)(c2ccccc2)C(C)(C)C)CC=C1OS(=O)(=O)C(F)(F)F

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 6/20 0.52
OPRM1 P35372 8/20 0.33
OPRL1 P41146 6/20 0.33
AKR1C3 P42330 1/20 0.32
SCN1A P35498 1/20 0.32
SCN2A Q99250 1/20 0.32
SCN3A Q9NY46 1/20 0.32
SMYD2 Q9NRG4 2/20 0.31
OPRD1 P41143 3/20 0.31
OPRK1 P41145 2/20 0.31
SLC6A2 P23975 2/20 0.31
SLC6A4 P31645 2/20 0.31
SLC6A3 Q01959 2/20 0.31
HTR1A P08908 1/20 0.31
DRD2 P14416 1/20 0.31
DRD1 P21728 1/20 0.31
DRD4 P21917 1/20 0.31
DRD5 P21918 1/20 0.31
HRH2 P25021 1/20 0.31
HTR1D P28221 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3229200 0.84 CCR2 (0.73) CCR2OPRM1OPRL1
SCHEMBL1780797 0.80 CCR2 (0.48) CCR2OPRM1OPRL1SCN1ASCN2A
SCHEMBL1779370 0.78 CCR2 (0.52) CCR2OPRM1OPRL1SCN1ASCN2A
SCHEMBL1781275 0.77 CCR2 (0.45) CCR2OPRM1OPRL1AKR1C3SCN1A
SCHEMBL1780401 0.74 CCR2 (0.43) CCR2OPRM1OPRL1SCN1ASCN2A
SCHEMBL3233950 0.70 CCR2 (0.82) CCR2
SCHEMBL1780892 0.69 CCR2 (1.00) CCR2
SCHEMBL6423008 0.66 SMYD2 (0.35) AKR1C3SMYD2DRD2DRD1DRD4
SCHEMBL6337190 0.66 SMYD2 (0.35) AKR1C3SMYD2DRD2DRD1DRD4
SCHEMBL6423010 0.66 SMYD2 (0.35) AKR1C3SMYD2DRD2DRD1DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8507559-B2 Cyclohexenyl modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2013-08-13 US disclosed
EP-2318352-B1 CYCLOHEXENYL COMPOUNDS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL MYERS SQUIBB CO (US) 2012-12-19 EP disclosed
US-20110118354-A1 CYCLOHEXENYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY 2011-05-19 US disclosed
EP-2318352-A2 CYCLOHEXENYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY Bristol-Myers Squibb Company (US) 2011-05-11 EP disclosed
WO-2010009068-A2 CYCLOHEXENYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY (US) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118354-A1 CYCLOHEXENYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY CCR1, CCR2, CCR3 CCR2 2/4885OPRM1 194/4885OPRL1 204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.